Camurus ABCAMRF 83 Debt-to-EBITDA is 0.14 as of Mar. 2026, which is 367% above its 10-year median of 0.03. GuruFocus rates CAMRF with a GF Score™ of 83/100 and a GF Value™ of $83.30 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 290 Biotechnology companies, Camurus AB ranks better than 81.72% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Camurus AB's Debt-to-EBITDA or its related term are showing as below:
CAMRF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.26 Med: 0.03 Max: 0.3
Current: 0.12
During the past 13 years, the highest Debt-to-EBITDA Ratio of Camurus AB was 0.30. The lowest was -0.26. And the median was 0.03.
CAMRF's Debt-to-EBITDA is ranked better than 81.72% of 290
companies
in the Biotechnology industry
Industry Median: 1.15
vs CAMRF: 0.12
Camurus AB (OTCPK:CAMRF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Camurus AB Debt-to-EBITDA Related Terms
Camurus AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Camurus AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Camurus AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Camurus AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Camurus AB (CAMRF) has a Debt-to-EBITDA of 0.14 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Camurus AB. This is 367% above median its historical median of 0.03. According to the industry distribution chart, Camurus AB ranks #53 out of 290 companies in the Biotechnology industry, placing it in the top 18.3%.
Is Camurus AB's Debt-to-EBITDA too high?
Camurus AB's current Debt-to-EBITDA of 0.14 is 367% above median its 10-year median of 0.03. The Biotechnology industry median Debt-to-EBITDA is 1.15. Camurus AB's value of 0.14 is 87.8% below this industry median. Based on the distribution chart, Camurus AB ranks #53 out of 290 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #53 out of 290 companies for Debt-to-EBITDA. This places Camurus AB in the top 18% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.15. Camurus AB's value of 0.14 is 87.8% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 1.15, Camurus AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 290 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Debt-to-EBITDA of 0.14 is 87.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Camurus AB. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Debt-to-EBITDA is 0.14, which is 367% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.30, compared to a current price of $60.00 — trading 28% below its estimated fair value. The current Debt-to-EBITDA is 0.14, which is 367% above median its 10-year median of 0.03 and 87.8% below the Biotechnology industry median of 1.15. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Debt-to-EBITDA is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $60.00 is trading 28% below its estimated GF Value™ of $83.30.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Debt-to-EBITDA: 0.14 (367% above median its 10-year median of 0.03)
GF Value™: $83.30 vs. price of $60.00 (28% below fair value)
Industry Position: 87.8% below the Biotechnology median (#53 of 290)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score
Get the complete analysis for CAMRF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
